Apyx medical corporation reports preliminary fourth quarter and full year 2023 revenue results

Clearwater, fla.--(business wire)--apyx medical corporation (nasdaq:apyx) (the “company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended december 31, 2023. preliminary fourth quarter 2023 revenue summary: total revenue in a range of approximately $14.2 to $14.6 million, representing growth of 13% to 16% year-over-year. advanced energy revenue in a.
APYX Ratings Summary
APYX Quant Ranking